Another Phase III Study Supports Avastin Expansion To Ovarian Cancer
This article was originally published in The Pink Sheet Daily
Executive SummaryAdding bevacizumab to chemo in first-line and maintenance therapy gives an undisclosed benefit in progression-free survival.
You may also be interested in...
Keeping Track: Keytruda Adds Two New Uses, Furoscix ‘Patch Pump’ Gets A CRL, And Nightstar Nabs An RMAT
Genentech says it worked closely with the agency to bring the drug to women with earlier-stage disease.